Literature DB >> 1726940

Human bcr-abl gene has a lethal effect on embryogenesis.

N Heisterkamp1, G Jenster, D Kioussis, P K Pattengale, J Groffen.   

Abstract

The chimaeric bcr-abl oncogene is thought to have a crucial role in the development or maintenance of chronic myelogenous leukaemia. To study this oncogene in a more direct way, the bcr-abl gene encoding the P210 protein under control of the bcr gene promoter was introduced into fertilized one-cell embryos, which were then re-implanted into foster mothers. Our data, obtained after several experiments, demonstrate that no live transgenic progeny could be obtained using this bcr-abl construct. The bcr gene is expressed in the course of embryogenesis and the bcr-abl gene product appears to have a pleiotropic lethal effect during this period of development. In concordance, several gross abnormalities were observed while no evidence of neoplastic formation was found. These results suggest that the bcr-abl encoded protein severely affects the process of normal embryogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726940     DOI: 10.1007/bf02512996

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  35 in total

1.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

2.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

3.  The Drosophila Abelson proto-oncogene homolog: identification of mutant alleles that have pleiotropic effects late in development.

Authors:  M J Henkemeyer; F B Gertler; W Goodman; F M Hoffmann
Journal:  Cell       Date:  1987-12-04       Impact factor: 41.582

4.  Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice.

Authors:  C J Quaife; C A Pinkert; D M Ornitz; R D Palmiter; R L Brinster
Journal:  Cell       Date:  1987-03-27       Impact factor: 41.582

5.  Developmental expression of PDGF, TGF-alpha, and TGF-beta genes in preimplantation mouse embryos.

Authors:  D A Rappolee; C A Brenner; R Schultz; D Mark; Z Werb
Journal:  Science       Date:  1988-09-30       Impact factor: 47.728

6.  Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.

Authors:  J B Konopka; S M Watanabe; J W Singer; S J Collins; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

7.  Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products.

Authors:  J B Konopka; O N Witte
Journal:  Mol Cell Biol       Date:  1985-11       Impact factor: 4.272

8.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia.

Authors:  A de Klein; A G van Kessel; G Grosveld; C R Bartram; A Hagemeijer; D Bootsma; N K Spurr; N Heisterkamp; J Groffen; J R Stephenson
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

9.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

Authors:  J Groffen; J R Stephenson; N Heisterkamp; A de Klein; C R Bartram; G Grosveld
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

10.  bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

Authors:  A G Elefanty; I K Hariharan; S Cory
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

View more
  13 in total

1.  Mouse models as tools to understand and study BCR-ABL1 diseases.

Authors:  Steffen Koschmieder; Mirle Schemionek
Journal:  Am J Blood Res       Date:  2011-06-07

Review 2.  Models of chronic myeloid leukemia.

Authors:  R A Van Etten
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

3.  Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development.

Authors:  E C Collins; R Pannell; E M Simpson; A Forster; T H Rabbitts
Journal:  EMBO Rep       Date:  2000-08       Impact factor: 8.807

Review 4.  The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.

Authors:  Richard A Van Etten; Steffen Koschmieder; Francois Delhommeau; Danilo Perrotti; Tessa Holyoake; Animesh Pardanani; Ruben Mesa; Tony Green; Amr R Ibrahim; Tariq Mughal; Robert Peter Gale; John Goldman
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

5.  Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.

Authors:  Samantha B Foley; Zacariah L Hildenbrand; Abigail A Soyombo; Jeffery A Magee; Yipin Wu; Katherine I Oravecz-Wilson; Theodora S Ross
Journal:  Cell Rep       Date:  2013-10-03       Impact factor: 9.423

Review 6.  Somatic Engineering of Oncogenic Chromosomal Rearrangements: A Perspective.

Authors:  Danilo Maddalo; Andrea Ventura
Journal:  Cancer Res       Date:  2016-08-12       Impact factor: 12.701

Review 7.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

Review 8.  Leukaemia and Sellafield: is there a heritable link?

Authors:  E J Tawn
Journal:  J Med Genet       Date:  1995-04       Impact factor: 6.318

9.  Establishment of reproducible xenotransplantation model of T cell acute lymphoblastic leukemia in NOD/SCID mice.

Authors:  Di Wang; Na Wang; Yan Zhang; Shuyan Ma; Zhe Geng; Pengfei Zhou; Jianfeng Zhou; Liang Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-08-11

10.  Expression of multiple gamma-glutamyltransferase genes in man.

Authors:  C Courtay; N Heisterkamp; G Siest; J Groffen
Journal:  Biochem J       Date:  1994-02-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.